BioSpace News Archive

Drug Development

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. today announced complete results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating ANEB-001 as a potential treatment for ACI in healthy volunteers challenged with oral delta-9-tetrahydrocannabinol (“THC”).

March 28, 2023
·
9 min read
Business

Freenome Adds Renown Health as Partner for the Sanderson Study

Freenome, a privately held biotech company announced that Renown Health has joined as a partner for the Sanderson Study, Freenome’s study of its multiomics platform, in combination with real-world data to detect multiple cancers.

March 28, 2023
·
4 min read
Business

iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.

March 28, 2023
·
22 min read
Business

SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.

March 28, 2023
·
16 min read
Business

Infinity Pharmaceuticals Reports Full Year 2022 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2022 financial results.

March 28, 2023
·
19 min read
Business

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.

March 28, 2023
·
21 min read
Genetown

Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 9:00 a.m. E.T in New York, NY.

March 28, 2023
·
1 min read
Business

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its fourth quarter ended December 31, 2022.

March 28, 2023
·
13 min read
Business

Biote Reports Fourth Quarter and Full Year 2022 Financial Results

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year ended December 31, 2022.

March 28, 2023
·
17 min read
Genetown

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company’s extraordinary general meeting.

March 28, 2023
·
4 min read